title: In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients.
abstract: The production and targeting of a major T cell derived lymphokine, Interleukin 2 (IL-2), were studied in 23 uremic patients undergoing regular hemodialysis treatment and 20 uremic patients prior to the onset of renal replacement therapy. In hemodialyzed patients, abnormally increased proportions of circulating T cells spontaneously expressing high affinity IL-2 receptors (IL-2 Rec) were detected: they bound a monoclonal antibody specifically directed to the IL-2 Rec 55 kDa chain (Tac antigen) (mean +/- SEM: 7.12 +/- 0.81% in patients vs. 2.15 +/- 0.39% in normal controls, P less than 0.0001) and significantly proliferated in presence of human recombinant IL-2 alone (mean +/- SEM: 5438 +/- 729 cpm in patients vs. 1647 +/- 244 cpm in normal controls). Hemodialyzed patients also exhibited significantly increased serum levels of soluble IL-2 receptor (mean +/- SEM: 4036 +/- 947 U/ml in patients vs. 253 +/- 29 U/ml in normal controls. P less than 0.001). Moreover, a significantly decreased IL-2 activity was detected in the supernatants of stimulated T cells from hemodialyzed patients (mean +/- SEM: 0.93 +/- 0.12 U/ml in patients vs. 2.49 +/- 0.22 U/ml in normal controls, P less than 0.0001). In nine hemodialyzed patients who were analyzed before and immediately after the hemodialysis session no acute modifications of the various parameters analyzed were detected. Although less profound, a similar pattern of T cell abnormalities was observed in the uremic non-hemodialyzed patients studied.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Inserm U 25, CNRS UA 122, Ass. Cl. Bernard Hôpital Necker, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Beaurain
authors.forename: C
authors.initials: C
authors.lastname: Naret
authors.forename: L
authors.initials: L
authors.lastname: Marcon
authors.forename: G
authors.initials: G
authors.lastname: Grateau
authors.forename: T
authors.initials: T
authors.lastname: Drueke
authors.forename: P
authors.initials: P
authors.lastname: Urena
authors.forename: D L
authors.initials: DL
authors.lastname: Nelson
authors.forename: J F
authors.initials: JF
authors.lastname: Bach
authors.forename: L
authors.initials: L
authors.lastname: Chatenoud
mesh_terms: D000328:Adult; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology*; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D006435:Renal Dialysis; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D007376:Interleukin-2; D015375:Receptors, Interleukin-2